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Abstract
Background Disease-modifying drugs are not yet available
for the management of chronic obstructive pulmonary
disease (COPD). HMG-CoA reductase inhibitors (statins)
have anti-inflammatory properties and are therefore being
considered for use in the management of COPD.
Objective Our objective was to examine the association
between statin use and COPD-specific outcomes in a real-
world setting.
Methods This was a retrospective longitudinal dynamic
cohort study that used Medicaid claims data from multiple
years (2005–2008) to identify patients with newly diag-
nosed COPD. Statin therapy was determined from the
prescription drug file using National Drug Codes (NDCs).
COPD-specific outcomes such as hospitalizations and
emergency room and outpatient visits were identified based
on a primary diagnosis of COPD. Multivariable logistic
regressions with inverse probability treatment weights
(IPTWs) were used to examine the relationship between
statin therapy and COPD-specific outcomes.
Results The study included 19,060 Medicaid beneficia-
ries with newly diagnosed COPD, 30.3% of whom
received statins during the baseline period. Adults who
received statins had significantly lower rates of COPD-
specific hospitalizations (4.7 vs. 5.2%; p\ 0.05), emer-
gency room visits (13.4 vs. 15.4%; p\ 0.001), and
outpatient visits (41.4 vs. 44.7%; p\ 0.001) than those
who did not receive statin therapy. Even after adjusting
for observed selection bias with IPTWs, adults receiving
statins were less likely to have COPD-specific hospital-
izations [adjusted odds ratio (AOR) 0.76; 95% confi-
dence interval (CI) 0.66–0.87], emergency room visits
(AOR 0.81; 95% CI 0.75–0.89), and outpatient visits
(AOR 0.86; 95% CI 0.80–0.91) than those not receiving
statins.
Conclusions Findings from this study suggest statins have
beneficial effects in patients with newly diagnosed COPD
and warrant further clinical trial investigation.
Key Points
This retrospective study using data from Medicaid
analytic extracts found the use of HMG-CoA
inhibitors (statins) among beneficiaries with newly
diagnosed chronic obstructive pulmonary disease
(COPD) may be associated with lower rates of
hospitalization and fewer emergency room and
outpatient visits.
Findings from the multivariable logistic regression
also showed that statin use was associated with a
lower likelihood of COPD-specific healthcare
resource use.
These study findings suggest improved outcomes
among statin users with COPD and thus warrant
further clinical trial investigation.
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1 Introduction
Treatment for chronic obstructive pulmonary disease
(COPD) currently focuses on reducing the frequency of
acute exacerbations and relieving the symptoms of COPD,
such as shortness of breath, through acute and maintenance
pharmacologic therapies and pulmonary rehabilitation [1].
To date, no therapeutic options that alter the prognosis of
COPD (also known as disease-modifying drugs) have been
established. The pathophysiology of the disease revolves
around local inflammation in the lungs [1]. However,
emerging understanding of COPD suggests the presence of
systemic inflammation among individuals with COPD [2–4].
It was recently documented that individuals with COPD are
more likely to have certain chronic conditions with common
inflammatory pathways than individuals without COPD.
These conditions include depression (20.6 vs. 12.5%),
coronary heart disease (12.7 vs. 6.1%), congestive heart
failure (12.1 vs. 3.9%), and stroke (8.9 vs. 4.6%) [5].
Unfortunately, the current acute and maintenance pharma-
cologic therapies for the management of COPD do not
specifically target this systemic inflammation [2, 6]. Thus,
researchers have been exploring the beneficial effects of
other medications that may lead to a reduction in systemic
inflammation among individuals with COPD [6–8].
1.1 Statins, Anti-Inflammatory Properties,
and Improved Outcomes Among Individuals
with Chronic Obstructive Pulmonary Disease
(COPD)
HMG-CoA inhibitors (statins) are a class of cholesterol-
lowering drugs that have demonstrated effectiveness in the
prevention and management of cardiovascular diseases [9].
Scho¨nbeck and Libby [10] reviewed in vitro and in vivo
studies and concluded that statins also have anti-inflamma-
tory properties. Several studies have shown statins to be of
benefit in reducing inflammatory biomarkers. Lee et al. [11]
found that smoking-related inflammation in the lungs of rats
was alleviated by a lipophilic statin (simvastatin). In humans,
a randomized controlled trial (RCT) showed that pravastatin
(hydrophilic statin) significantly reduced levels of inflam-
matory biomarkers [12]. This evidence is also supported by
preclinical models that have revealed the pleiotropic/anti-
inflammatory therapeutic benefits attributable to statins [13].
Documented evidence of the beneficial effects of statins
on outcomes among individuals with COPD also exists.
One randomized trial [12] and some observational studies
[14–18] have examined the role of statins in the manage-
ment of COPD. Most of these studies have provided evi-
dence of the beneficial effects of statins in improving lung
function [14] and exercise time as a measure of health
status [12] and in reducing COPD exacerbations [16] and
all-cause [15, 19–21] and COPD-specific mortality [19].
However, only a handful of studies have examined the
effects of statins on COPD-specific clinical outcomes such
as hospitalizations in a real-world practice setting.
A time-matched nested case–control study on the effects
of statins in elderly individuals with COPD indicated that,
compared with no statin use, any statin use was associated
with a reduced likelihood of COPD-related hospitalization
irrespective of their cardiovascular risk [high cardiovas-
cular risk: risk ratio (RR) 0.71; 95% confidence interval
(CI) 0.56–0.91; low cardiovascular risk: RR 0.71; 95% CI
0.64–0.77] [20]. These findings were similar to those from
a nationwide cohort study in Taiwan [17] reporting that,
among 6252 individuals with newly diagnosed COPD,
statin use significantly decreased the hazard ratio (HR) of
COPD-related hospitalization (HR 0.66; 95% CI
0.60–0.74) compared with no statin use.
These studies have several limitations that restrict our
ability to better understand the relationship between statin
therapy and COPD-specific health outcomes. Keddissi
et al. [14] assessed the impact of statin use among veterans
with COPD but had a limited sample size of only 418
individuals and only represented hospitalized patients who
were either former or current smokers. The other studies
that evaluated the use of statins for improving COPD-
specific outcomes had other issues in terms of generaliz-
ability to the general US population. For example, some
papers were based on non-US populations [17, 20],
whereas others were conducted among specific subgroups
such as those with COPD and cardiovascular risk [20].
Therefore, the primary objective of this study was to
evaluate the relationship between statins and COPD-
specific outcomes such as hospitalizations and emergency
room and outpatient visits in a US population seeking care
in real-world practice settings.
2 Methods
2.1 Study Design
This was a retrospective longitudinal dynamic cohort study
to examine the relationship between statins and COPD-
specific clinical outcomes. Two separate 2-year panels
using data from multiple years (2005–2008) were created
in which Medicaid beneficiaries with diagnosed COPD
were identified in the years 2006 and 2007. We used the
first service date with a COPD diagnosis as the index date.
A detailed description of the procedure used to identify the
study population is provided in the following sections. Two
distinct study observation periods consisted of the baseline
period (defined as 1 year before the index date) and follow-
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up period (defined as 1 year after the index date). The
baseline period was used to assess statin use and other
beneficiary characteristics, whereas the follow-up period
was used to ascertain COPD-specific clinical outcomes.
2.2 Data Source
Medicaid analytic extract (MAX) files containing infor-
mation on enrollment, inpatient visits, other therapy, and
the use of prescription drugs were used [22]. The personal
summary file provided information on eligibility, demo-
graphics (age, sex, and race), managed care enrollment,
and utilization summary. The other four files contained
information on fee-for-service claims for services used.
Other therapy files included information regarding claims
for Medicaid services provided at an outpatient level such
as clinic, physician, laboratory, and home-health services.
Hospitalization diagnosis codes, procedures, length of stay
for each hospitalization, and expenditures related to hos-
pitalizations were extracted from the inpatient files.
National drug codes (NDCs) for prescription drugs, supply
days, fill dates, and payments for prescription drugs were
obtained from the prescription drug files.
We used data for beneficiaries residing in California
(CA), Illinois (IL), New York (NY), and Texas (TX).
These states were chosen to capture the diverse geographic
and racial/ethnic populations represented by Medicaid.
2.2.1 Area Resource File
We also determined each Medicaid beneficiary’s contex-
tual county-level variables using the area resource file
(ARF), a comprehensive county-level dataset compiled by
the Health Resources & Services Administration Bureau of
Health Professions. It contains more than 6000 variables
providing information about the nation’s counties. The
information contained within the ARF includes type of
health facilities in the various counties, number and type of
health professions, resource scarcity measures, health sta-
tus, economic activity, health training programs, and
socioeconomic and environmental characteristics. These
files also include county codes and descriptors that enable
linkage with several secondary datasets such as MAX. We
used the county codes and state information to link MAX
files with the 2005 ARF file.
2.3 Study Population: Medicaid Beneficiaries
with Newly Diagnosed COPD
Medicaid beneficiaries with diagnosed COPD were iden-
tified using inpatient and outpatient visits (physician office
visits and clinic services only). Medicaid beneficiaries with
at least one inpatient visit or two outpatient visits 14 days
apart (obtained using type of service codes) for COPD
based on International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes for
chronic bronchitis (491.xx), emphysema (492.xx), or
unspecified chronic airway obstruction (496.xx) were
considered to have diagnosed COPD. These diagnosis
codes have been used in published research to identify
COPD and evaluate medical treatment and health outcomes
among individuals with COPD [23–25], and the sensitivity
and specificity of using these codes to identify patients with
COPD has been established [26, 27]. Gershon et al. [27]
reported that identifying COPD using one or more ambu-
latory claims and/or one or more hospitalizations for
COPD resulted in a sensitivity of 85.0% (95% CI
77.0–91.0) and a specificity of 78.4% (95% CI 73.6–82.7).
However, we used one inpatient claim or at least two
outpatient claims to identify individuals with COPD to
increase the specificity of the algorithm. We only included
Medicaid beneficiaries with newly diagnosed COPD. To
obtain the data for these individuals, we created a washout
period (1 year prior to the index date of COPD diagnosis).
Only Medicaid beneficiaries who did not have a COPD
diagnosis in the washout period were considered to have
newly diagnosed COPD and included in our study
population.
Other inclusion criteria included (1) aged 40–64 years
as of the index date (among young adults, this age group is
at highest risk of COPD), (2) continuous eligibility during
the baseline and follow-up periods, (3) no dual Medicaid/
Medicare coverage (dual eligibility represents high-cost
and severely ill beneficiaries), (4) enrolled in fee-for-ser-
vice plans throughout the study observation period, (5)
alive during the study observation period, (6) and use of
services (inpatient or outpatient).
2.4 Dependent Variables: COPD-Specific Outcomes
The following variables were identified as COPD-specific
outcomes: (1) COPD-specific hospitalizations (yes/no), (2)
COPD-specific emergency room visits (yes/no) obtained
from inpatient and outpatient claims, and (3) COPD-
specific outpatient visits (low and high) derived by cate-
gorizing the number of COPD-specific outpatient visits
greater than or equal to the median and less than the
median value. Any healthcare claim with a primary diag-
nosis of COPD identified using ICD-9-CM codes was
considered within COPD-specific outcomes.
2.5 Key Independent Variable: Statin Therapy
(Yes/No)
Statin therapy was identified in the baseline period using
the NDCs. Any Medicaid beneficiary with at least one
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prescription of a statin during the baseline period was
considered to be a statin therapy user.
2.6 Other Independent Variables
These variables included year of diagnosis (2006 vs. 2007),
demographic characteristics such as sex (women, men),
race (White, African American, other), age in years
(40–49, 50–59, 60–64), poverty eligibility (yes, no), med-
ical eligibility (yes, no), number of clinical conditions
(none, 1–3, 4–6, [6), serious mental illness (yes, no),
alcohol abuse (yes, no), substance abuse (yes, no), tobacco
use (yes, no), and polypharmacy (fewer than ten drug
classes, ten or more drug classes). We also controlled for
county-level characteristics obtained from the ARF.
Quartiles for density of above high school education,
unemployment, poverty, primary care providers, and spe-
cialist care providers were created. The density of these
county-level characteristics was calculated by dividing the
total number of each characteristic by the total county
population. This density was further converted into per
1000 people by multiplying 1000 with the density. Other
ARF characteristics included pulmonologist density (high
vs. low) and cardiologist density (high vs. low), among
others. In addition to these variables, there is a possibility
of bias in the relationship between statin therapy and
COPD-specific outcomes because of variations in state
policies. Therefore, we adjusted for fixed effects for state
variations using a dummy variable for the states (CA, IL,
NY, TX) in our analyses.
We also controlled for the presence of common multi-
morbidity by constructing binary indicator variables to
indicate the presence of common inflammatory conditions,
including arthritis, cardiovascular disease, depression, dia-
betes, hypertension, hyperlipidemia, and osteoporosis using
ICD-9-CM codes. We further categorized the multimorbid-
ity variable into a binary categorical variable (yes/no).
2.7 Statistical Analyses
2.7.1 Bivariate Analyses
Subgroup differences in statin therapy and duration of
statin therapy were tested using Chi squared tests of
independence, as were bivariate differences in COPD-
specific healthcare outcomes between those receiving and
not receiving statin therapy.
2.7.2 Multivariate Analyses
To account for selection bias due to observed differences in
baseline characteristics among individuals with and without
statin therapy, we used inverse probability of treatment
weighting (IPTW). This allowed us to calculate weights that
were essentially the probability of an individual receiving the
treatment (i.e., exposure in a non-randomized study) condi-
tional on their observed stable covariates. Higher weights
were assigned to individuals who were under-represented
and lower weights were assigned to those who were over
represented. We adjusted for the probability weight that we
obtained from the logistic/multinomial logistic regressions
on statin therapy and duration of statin therapy, respectively,
to control for the observed selection bias. This created a
balance in terms of distribution of potential confounders
across treatment levels. The literature [28] has shown this
method performs better than matching-based methods when
the prevalence of treatment is relatively not extreme, which
is the case in our study cohort (30%).
We used logistic regressions and multinomial logistic
regressions to examine the factors associated with any
statin and long-term statin therapy, respectively. Multi-
variable logistic regressions with and without IPTW
adjustment were used to determine the relationship
between statin therapy and COPD-specific outcomes.
We used logistic regression to analyze the relationship
between statin therapy, presence of multimorbidity, and
COPD-specific healthcare outcomes. We created a variable
with four categories: (1) statin therapy and multimorbidity,
(2) no statin therapy and multimorbidity, (3) statin therapy
and no multimorbidity, and (4) no statin therapy and
multimorbidity. All analyses were conducted using SAS
9.3 (SAS Institute, Cary, NC, USA).
3 Results
After applying the eligibility criteria as shown in Fig. 1, the
analytic cohort included 19,060 Medicaid beneficiaries
with newly diagnosed COPD. Any statin therapy was
observed in 30.3% (n = 5771) of the Medicaid beneficia-
ries, three-quarters of whom received long-term statin
therapy, defined as C120 days of statin medication supply.
3.1 Factors Associated with Statin Therapy
Several demographic and clinical factors were associated
with statin therapy and duration of statin therapy among
Medicaid beneficiaries with newly diagnosed COPD
(Table 1). We found significant differences between statin
users and non-users, so we performed a multivariable
logistic regression that adjusted for multimorbidity, number
of other clinical conditions, year of observation, sex, race/
ethnicity, age, state, serious mental illness, alcohol use,
substance use, and polypharmacy. This regression was used
to calculate the IPTWs. We checked the balance of the
explanatory variables before and after IPTW adjustment and
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observed that the group differences in statin use were no
longer significant after IPTW adjustment (Table 1).
3.2 Statin Therapy and COPD-Specific Outcomes
As shown in Table 2, individuals receiving statin therapy
had significantly lower rates of COPD-specific hospital-
izations (4.7 vs. 5.2%; p\ 0.05), COPD-specific emer-
gency room visits (13.4 vs. 15.4%; p\ 0.001), and COPD-
specific outpatient visits (41.4 vs. 44.7%; p\ 0.001) than
adults who were not receiving statin therapy. Similarly,
beneficiaries with any duration of statin therapy (long-term
or short-term) had lower rates of COPD-specific healthcare
utilization. The reduction in COPD-specific healthcare
utilization was also observed even after controlling for
baseline characteristics. Beneficiaries receiving statin
therapy were 16% less likely to have COPD-specific hos-
pitalization [adjusted odds ratio (AOR) 0.84; 95% CI
0.71–0.98], 11% less likely to have COPD-specific emer-
gency room visits (AOR 0.89; 95% CI 0.81–0.99), and
14% less likely to have COPD-specific outpatient visits
(AOR 0.86; 95% CI 0.80–0.92). To control for selection
bias in observed variables, we conducted the same
regression analyses after weighting with IPTWs obtained
from logistic and multinomial logistic regressions on statin
therapy and duration of statin therapy, respectively. These
treatment weights were adjusted for the number of indi-
viduals in each category of statin therapy and duration of
2,422 beneficiaries died during the 
study observation period
23,289 dual Medicare/Medicaid 
eligible
7,025 individuals without 
continuous eligibility
59,536 individuals with newly diagnosed 
Chronic Obstructive Pulmonary Disease 
(COPD) diagnosis between January 1, 2006, 
and December 31, 2007 in 
Medicaid Analytic eXtract Files
57,114 beneficiaries with newly diagnosed 
COPD were alive during the entire study 
observation period
33,825 individuals with no dual eligibility
26,800 beneficiaries with continuous eligibility 
throughout study observation period
3,589 enrollees with HMO plans




between 40-64 years with 
newly diagnosed COPD
4,151 enrollees aged <40 years or 
>64 years
5,771 statin users 13,289 non-users
Fig. 1 Selection of study
population
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Table 1 Patient characteristics by statin (pre- and post- inverse probability treatment weighting)
Characteristic Pre-inverse probability treatment weighting Post-inverse probability treatment weighting
Statin use No statin use p value Statin use No statin use p value
N Row (%) N Row (%) Row (wt%) Row (wt%)
Total 5771 30.1 13,289 69.9
Multimorbidity categories \0.0001 0.887
Physical only 3639 39.1 5668 60.9 30.3 69.7
Mental only 184 14.3 1099 85.7 31.3 68.7
Both 1345 36.0 2388 64.0 30.3 69.7
None 603 12.7 4134 87.3 30.2 69.8
Cohort year 0.007 0.436
2005–2007 3161 29.5 7560 70.5 30.5 69.5
2006–2008 2610 31.3 5729 68.7 30.0 70.0
Sex 0.000 0.421
Women 3646 32.2 7688 67.8 30.5 69.5
Men 2125 27.5 5601 72.5 30.0 70.0
Age (years) \0.0001 0.838
40–49 1386 21.8 4958 78.2 30.6 69.4
50–59 2942 31.9 6292 68.1 30.1 69.9
60–64 1443 41.4 2039 58.6 30.3 69.7
Race/ethnicity \0.0001 0.836
White 2935 31.7 6337 68.3 30.1 69.9
African–American 1231 24.2 3854 75.8 30.4 69.6
Others 1605 34.1 3098 65.9 30.6 69.4
State \0.0001 0.791
California 3179 30.6 7218 69.4 30.5 69.5
Illinois 1257 30.6 2853 69.4 29.7 70.3
New York 854 32.7 1761 67.3 30.3 69.7
Texas 481 24.8 1457 75.2 30.8 69.2
Number of clinical conditions \0.0001 0.961
None 74 15.6 399 84.4 31.0 69.0
1–3 835 23.5 2713 76.5 30.0 70.0
4–6 1268 28.3 3205 71.7 30.5 69.5
[6 3594 34.0 6972 66.0 30.3 69.7
SMI \0.0001 0.045
Yes 1299 26.2 3665 73.8 31.4 68.6
No 4472 31.7 9624 68.3 29.9 70.1
Alcohol abuse \0.0001 0.808
Yes 318 17.4 1506 82.6 30.6 69.4
No 5453 31.6 11,783 68.4 30.3 69.7
Substance abuse \0.0001 0.272
Yes 457 17.3 2183 82.7 31.2 68.8
No 5314 32.4 11,106 67.6 30.2 69.8
Polypharmacy \0.0001 0.515
Yes 4361 44.2 5502 55.8 30.5 69.5
No 1410 15.3 7787 84.7 30.1 69.9
Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD obtained from Medicaid analytic extract files observed during 2005–2008. IPTWs
were derived from a logistic regression on statin use with adjustments for all the variables included in the table. Row percentages reflect the percentage of
non-users among subgroups with specific characteristics
COPD chronic obstructive pulmonary disease, IPTWs inverse probability treatment weights, SMI serious mental illness, Wt weighted
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statin therapy. The results from these analyses are pre-
sented in Table 3. Even after using IPTW, we found that
individuals receiving statin therapy were significantly less
likely to have COPD-specific healthcare outcomes. In fact,
the magnitude of reduction and significance strength was
enhanced after controlling for selection bias using the
IPTW technique.
3.3 Statin Therapy, Multimorbidity, and COPD-
Specific Healthcare Outcomes
We analyzed the relationship between statin therapy and
COPD-specific healthcare outcomes in the presence of
multimorbidity and found that beneficiaries with multi-
morbidity receiving statin therapy were less likely to have
COPD-specific healthcare outcomes than those with mul-
timorbidity not receiving statin therapy. For example,
beneficiaries with multimorbidity receiving statin therapy
were 18% less likely to have COPD-specific hospitalization
(AOR 0.82; 95% CI 0.70–0.97) than those with multi-
morbidity not receiving statin therapy. Detailed results are
presented in Table 4.
3.4 Secondary Analyses: Duration of Statin
Therapy (Long-Term/Short-Term/No Statin
Therapy)
Individuals receiving long-term statin therapy were dif-
ferentiated from those receiving short-term statin therapy.
Medicaid beneficiaries with newly diagnosed COPD with
C120 days of statin supply during the baseline period were
considered to be receiving long-term therapy. Individuals
with \120 days of statin supply were categorized as
receiving short-term statin therapy, and those without any
statin claim were grouped under ‘no statin’ therapy.
Analyses of duration of statin therapy revealed that only
long-term statin therapy was associated with lower COPD-
specific healthcare outcomes. Beneficiaries receiving long-
term statin therapy were less likely to have COPD-specific
hospitalizations (AOR 0.81; 95% CI 0.71–0.99), COPD-
specific emergency room visits (AOR 0.86; 95% CI
0.77–0.96), and COPD-specific outpatient visits (AOR 0.84;
95% CI 0.78–0.92) (data not represented in tabular form).
Moreover, after using IPTW, short-term statin therapy
also showed significant reductions in COPD-specific











Yes 270 4.7 0.84 0.71–0.98 *
No 728 5.5
COPD-specific emergency room visits
Total 2824 14.8
Statin therapy ***





Yes 2032 41.4 0.86 0.80–0.92 ***
No 5168 44.7
Based on 19,060 Medicaid beneficiaries with newly diagnosed COPD obtained from Medicaid analytic
extract files observed during 2005–2008. Asterisks represent significant group differences in likelihood of
COPD-specific healthcare utilization by statin therapy compared with the reference group (none) obtained
from adjusted logistic regression analyses. Adjusted logistic regressions controlled for cohort year, sex,
race, age, state, poverty eligibility, multimorbidity number of other clinical conditions, serious mental
illness, alcohol abuse, substance abuse, tobacco use, polypharmacy, county-level variables, including above
high school education density (quartiles), unemployment density (quartiles), poverty density (quartiles),
metro status, primary care shortage area, mental health shortage area, primary care provider density
(quartiles), hospital beds density (quartiles), psychiatric hospital, pulmonologist density and cardiologist
density
AOR adjusted odds ratio, CI confidence interval, COPD chronic obstructive pulmonary disease
* 0.01 B p\ 0.05
** 0.001 B p\ 0.01
*** p\ 0.001
Statins and COPD-Specific Outcomes 15
hospitalizations (AOR 0.83; 95% CI 0.75–0.91) (Table 5).
However, the association between short-term statin therapy
and COPD-specific emergency room visits and COPD-
specific outpatient visits remained insignificant. We also
conducted sensitivity analyses using unadjusted IPTW
(using weights that were not adjusted for the number of
individuals receiving statins). The results from the sensi-
tivity analyses were similar to those observed with the
adjusted IPTW. They are not represented in tabular form
but are available upon request.
4 Discussion
This retrospective observational study was conducted to
evaluate the COPD-specific outcomes associated with sta-
tin therapy among individuals with newly diagnosed COPD
in a real-world practice setting. Approximately 30% of
Medicaid beneficiaries with newly diagnosed COPD
received statins during the baseline period. In this study,
we found that even after controlling for baseline charac-
teristics and observed selection bias using IPTW, benefi-
ciaries receiving statins were 24% less likely to have
COPD-specific hospitalizations, 19% less likely to have
COPD-specific emergency room visits, and 14% less likely
to have COPD-specific outpatient visits among individuals
with newly diagnosed COPD. Our results are consistent
with those of a handful of studies that found beneficial
effects when evaluating the effects of statins in terms of
COPD-related hospitalizations [17, 20]. However, to the
Table 3 Logistic regressions on chronic obstructive pulmonary dis-
ease-specific healthcare utilization among Medicaid beneficiaries
with newly diagnosed chronic obstructive pulmonary disease
(n = 19,060); inverse probability treatment weight adjustment
AOR 95% CI Significance
COPD-specific hospitalizations
Statin therapy
Yes 0.79 0.68–0.92 **
No
COPD-specific emergency room visits
Statin therapy




Yes 0.87 0.81–0.93 ***
No
Based on 19,060 Medicaid Beneficiaries with newly diagnosed COPD
obtained from Medicaid analytic extract files observed during
2005–2008. Asterisks represent significant group differences in
COPD-specific healthcare utilization by statin therapy compared with
non-users. Adjusted logistic regressions controlled for cohort year,
sex, race, age, state, poverty eligibility, multimorbidity number of
other clinical conditions, serious mental illness, alcohol, substance
abuse, tobacco use, polypharmacy, and county variables, including
above high school education (quartiles), unemployment density
(quartiles), poverty density (quartiles), metro status, primary care
shortage area, mental health shortage area, primary care provider
density (quartiles), hospital beds density (quartiles), psychiatric hos-
pital, pulmonologist density, and cardiologist density
AOR adjusted odds ratio, CI confidence interval, COPD chronic
obstructive pulmonary disease
* 0.01 B p\ 0.05
** 0.001 B p\ 0.01
*** p\ 0.001
Table 4 Logistic regressions on chronic obstructive pulmonary dis-
ease-specific healthcare utilization among Medicaid beneficiaries
with newly diagnosed chronic obstructive pulmonary disease
(n = 19,060)
AOR 95% CI Significance
COPD-specific hospitalizations
MM and statin therapy 0.82 0.70–0.97 *
MM and no statin therapy Reference
No MM and statin therapy 0.98 0.67–1.46
No MM and no statin therapy 1.17 0.98–1.39
COPD-specific emergency room visits
MM and statin therapy 0.90 0.81–0.99 *
MM and no statin therapy Reference
No MM and statin therapy 0.99 0.77–1.27
No MM and no statin therapy 1.17 1.05–1.31 **
COPD-specific outpatient visits
MM and statin therapy 0.85 0.78–0.92 ***
MM and no statin therapy Reference
No MM and statin therapy 0.88 0.73–1.05
No MM and no statin therapy 0.95 0.87–1.03
Based on 19,060 Medicaid beneficiaries with newly diagnosed COPD
obtained from Medicaid analytic extract files observed during
2005–2008. Asterisks represent significant group differences in like-
lihood of COPD-specific healthcare utilization by statin ther-
apy/multimorbidity interaction categories compared with the
reference group (no statin and no multimorbidity) obtained from
adjusted logistic regression analyses. Adjusted logistic regressions
controlled for cohort year, sex, race, age, state, poverty eligibility,
multimorbidity number of other clinical conditions, serious mental
illness, alcohol abuse, substance abuse, tobacco use, polypharmacy,
county level variables including: above high school education density
(quartiles), unemployment density (quartiles), poverty density (quar-
tiles), metro status, primary care shortage area, mental health shortage
area, primary care provider density (quartiles), hospital beds density
(quartiles), psychiatric hospital, pulmonologist density, and cardiol-
ogist density
AOR adjusted odds ratio, CI confidence interval, COPD chronic
obstructive pulmonary disease, MM multimorbidity
* 0.01 B p\ 0.05
** 0.001 B p\ 0.01
*** p\ 0.001
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best of our knowledge, this is the first study to examine the
relationship between statin therapy and COPD-specific
outcomes. Furthermore, this is the only study to assess the
impact of duration of statin therapy among individuals with
newly diagnosed COPD. Findings from this study indicate
that a beneficial impact of statins is directly related to the
duration of statin therapy. Statistically significant reduc-
tions in COPD-specific emergency room visits and outpa-
tient visits were only observed among beneficiaries who
had C120 days of statin medication supply during the
baseline period.
In addition, our study findings also revealed that statin
therapy was associated with additional benefits for adults
with COPD and multimorbidity (Table 4) compared with
those with multimorbidity and no statin therapy. Such
additional benefits could potentially be explained by the
anti-inflammatory properties of statin therapy. Biologi-
cally, reductions in inflammatory biomarkers indicate statin
therapy has anti-inflammatory properties [29, 30]. As
COPD is becoming recognized as a disease of systemic
inflammation with high levels of inflammatory biomarkers
[8, 31, 32], the results from our analyses suggest that the
biological benefits of statins in reducing systemic inflam-
mation may also reduce COPD-specific complications.
Moreover, statins have been shown to improve outcomes
among patients with cardiovascular comorbidities, which is
a primary cause of mortality among patients with COPD.
The association between COPD, systemic inflammation,
and cardiovascular mortality is very important since the
majority of patients with COPD die from cardiovascular
causes, and lung function is a predictor of all-cause and
cardiac-specific mortality [33]. Thus, the accepted benefits
of statins in treating cardiovascular diseases can be linked
to improvement in COPD-specific outcomes among
patients with newly diagnosed COPD.
Findings from this study add to the existing evidence
that suggest the beneficial impact of statins on improved
lung function, COPD symptoms, and exacerbations
[14–18]. Collectively, these findings warrant the evaluation
of statins in RCTs to establish the efficacy and safety of
statin use among individuals with COPD. Some RCTs that
were ongoing when we conceptualized the study have
recently been completed [34–36]. Findings from one of
these large prospective multicenter RCTs evaluating the
efficacy of simvastatin on reducing COPD exacerbations
differed from the conclusions of our study [34]. This may
be due to differences in the study population, as the trial
included individuals with moderate to severe COPD aged
between 40 and 80 years, whereas our study included
patients with newly diagnosed COPD aged between 40 and
64 years. Moreover, the trial specifically evaluated the
efficacy of simvastatin. Therefore, more robust evaluations
of all statins is required in both RCTs and real-world
practice settings with longer follow-up to confirm the
beneficial effects of statins that we observed in our study.
Indeed, a recent analyses of the STATins in COPD Exac-
erbations (STATCOPE) trial indicates deficiencies in the
trial and warrants the need for further analyses of statins
among patients with COPD eligible to receive statins [37].
4.1 Strengths and Limitations
This study is the first real-world observational analyses of
clinical and economic outcomes associated with statin
therapy among patients with newly diagnosed COPD in a
US setting. The major strength of our study is the use of
administrative claims data that enabled us to identify all the
medical conditions using diagnosis codes. The data also
Table 5 Logistic regressions on chronic obstructive pulmonary dis-
ease-specific healthcare utilization among Medicaid beneficiaries
with newly diagnosed chronic obstructive pulmonary disease; inverse
probability treatment weight adjustment
AOR 95% CI Significance
COPD-specific hospitalizations
Duration of statin therapy
Long-term 0.73 0.66–0.80 ***
Short-term 0.83 0.75–0.91 ***
No use
COPD-specific emergency room visits
Duration of statin therapy




Duration of statin therapy
Long-term 0.84 0.77–0.90 ***
Short-term 0.89 0.79–1.00
No use
Based on 19,060 Medicaid beneficiaries with newly diagnosed COPD
obtained from Medicaid analytic extract files observed during
2005–2008. Asterisks represent significant group differences in like-
lihood of COPD-specific healthcare utilization by duration of statin
therapy compared with no statin use. Adjusted logistic analyses
controlled for cohort year, sex, race, age, state, poverty eligibility,
multimorbidity number of other clinical conditions, serious mental
illness, alcohol, substance abuse, tobacco use, polypharmacy, county
variables including: above high school education (quartiles), unem-
ployment density (quartiles), poverty density (quartiles), metro status,
primary care shortage area, mental health shortage area, primary care
provider density (quartiles), hospital beds density (quartiles), psy-
chiatric hospital, pulmonologist density, and cardiologist density
AOR adjusted odds ratio, CI confidence interval, COPD chronic
obstructive pulmonary disease
* 0.01 B p\ 0.05
** 0.001 B p\ 0.01
*** p\ 0.001
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consisted of medication information with NDCs and days
of medication supply information, which helps in deter-
mining duration of statin therapy. Furthermore, our study
examined a high-risk vulnerable population in terms of
Medicaid enrollees. The current study differs from any
prior analyses as it evaluated the effects of statin therapy on
COPD-specific outcomes.
This study has some limitations common among
observational studies based on claims data. For example,
we were not able to control for COPD severity because
laboratory data were unavailable. Our study population was
determined using ICD-9-CM codes rather than the gold
standard approach of using spirometry laboratory values.
However, the sensitivity and specificity of ICD-9-CM
codes to identify COPD has been established in previous
studies. The study used data from only four states, which
does not provide a full coverage of US Medicaid popula-
tion. We also excluded dual Medicare–Medicaid and
managed care enrollees from our population, which limits
the overall generalizability. Finally, our study is only
generalizable to patients with newly diagnosed COPD;
further research is required to evaluate the effectiveness of
statin therapy among individuals with prevalent COPD.
Despite these limitations, this is the first real-world
observational study to comprehensively examine the rela-
tionship between statin medications and COPD-specific
outcomes in a US population. Findings from this study
warrant further clinical trial investigation of statin use
among individuals with COPD.
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